Literature DB >> 31296280

Meta-analysis of the Cepheid Xpert® CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections.

Claire C Bristow1, Sheldon R Morris2, Susan J Little2, Sanjay R Mehta2, Jeffrey D Klausner3.   

Abstract

Background Most studies evaluating extragenital testing performance for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) detection by the Xpert® CT/NG show high per cent agreement with comparison assays; however, the precision around positive per cent agreement is low and thus the values that have been reported are not highly informative. Therefore, a systematic review was conducted and data from five studies were combined to better assess positive per cent agreement.
METHODS: The literature indexed on PubMed.gov was searched. Included studies were those that were an evaluation of the Xpert CT/NG assay with rectal and/or pharyngeal specimen types compared with another nucleic acid amplification test (NAAT), the Aptima transcription mediated amplification assay. A full Bayesian method was used for bivariate fixed-effect meta-analysis of positive and negative per cent agreement and pooled estimates (and 95% confidence intervals (CI)) were presented for each.
RESULTS: The pooled positive and negative per cent agreement for detection of CT in rectal specimens was 89.72% (95% CI: 84.97%, 93.64%) and 99.23% (95% CI: 98.74%, 99.60%), and in pharyngeal specimens, they were 89.96% (95% CI: 66.38%, 99.72%) and 99.62% (95% CI: 98.95%, 99.95%) respectively. For NG detection in rectal specimens, the pooled positive and negative per cent agreement was 92.75% (95% CI: 87.91%, 96.46%) and 99.75% (95% CI: 99.46%, 99.93%), and in pharyngeal specimens, they were 92.51% (95% CI: 85.84%, 97.18%) and 98.56% (95% CI: 97.69%, 99.23%) respectively.
CONCLUSIONS: It was found that the Xpert CT/NG assay performed similarly to the Aptima transcription mediated amplification assay for the detection of CT and NG in extragenital specimens. The Xpert assay has the benefit of providing faster results at the point-of-care, thus reducing the turnaround time for results, potentially enabling same-day treatment.

Entities:  

Mesh:

Year:  2019        PMID: 31296280      PMCID: PMC6954977          DOI: 10.1071/SH18079

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  28 in total

1.  Bivariate random-effects meta-analysis of sensitivity and specificity with the Bayesian SAS PROC MCMC: methodology and empirical evaluation in 50 meta-analyses.

Authors:  Jan Menke
Journal:  Med Decis Making       Date:  2013-03-08       Impact factor: 2.583

2.  Comparison of the Abbott m2000 RealTime CT assay and the Cepheid GeneXpert CT/NG assay to the Roche Amplicor CT assay for detection of Chlamydia trachomatis in ocular samples from Tanzania.

Authors:  Laura Dize; Sheila West; James A Williams; Barbara Van Der Pol; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

3.  Comparison of the Cepheid GeneXpert CT/NG assay to the Hologic Aptima Combo2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in self-collected rectal swabs.

Authors:  Laura Dize; Barbara Silver; Charlotte Gaydos
Journal:  Diagn Microbiol Infect Dis       Date:  2017-10-26       Impact factor: 2.803

4.  Evidence for increased Chlamydia case finding after the introduction of rectal screening among women attending 2 Canadian sexually transmitted infection clinics.

Authors:  Jennifer Gratrix; Ameeta E Singh; Joshua Bergman; Caroline Egan; Sabrina S Plitt; Justin McGinnis; Christopher A Bell; Steven J Drews; Ron Read
Journal:  Clin Infect Dis       Date:  2014-10-21       Impact factor: 9.079

5.  Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis.

Authors:  B Van Der Pol; T C Quinn; C A Gaydos; K Crotchfelt; J Schachter; J Moncada; D Jungkind; D H Martin; B Turner; C Peyton; R B Jones
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Comparison of three nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens.

Authors:  Charlotte A Gaydos; Mellisa Theodore; Nicholas Dalesio; Billie Jo Wood; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens.

Authors:  C A Gaydos; T C Quinn; D Willis; A Weissfeld; E W Hook; D H Martin; D V Ferrero; J Schachter
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Use of Nucleic Acid Amplification Testing for Diagnosis of Extragenital Sexually Transmitted Infections.

Authors:  Lisa A Cosentino; Claire S Danby; Lorna K Rabe; Ingrid Macio; Leslie A Meyn; Harold C Wiesenfeld; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2017-07-05       Impact factor: 5.948

9.  Patterns of Extragenital Chlamydia and Gonorrhea in Women and Men Who Have Sex With Men Reporting a History of Receptive Anal Intercourse.

Authors:  Claire S Danby; Lisa A Cosentino; Lorna K Rabe; Carol L Priest; Khrystine C Damare; Ingrid S Macio; Leslie A Meyn; Harold C Wiesenfeld; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2016-02       Impact factor: 2.830

10.  Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits.

Authors:  Gary G Whitlock; Daniel C Gibbons; Nick Longford; Michael J Harvey; Alan McOwan; Elisabeth J Adams
Journal:  Int J STD AIDS       Date:  2017-10-23       Impact factor: 1.359

View more
  6 in total

1.  Point-by-Point Progress: Gonorrhea Point of Care Tests.

Authors:  Charlotte A Gaydos; Johan H Melendez
Journal:  Expert Rev Mol Diagn       Date:  2020-06-30       Impact factor: 5.225

2.  Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: Systematic review and value proposition development.

Authors:  Sebastian S Fuller; Eleanor Clarke; Emma M Harding-Esch
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

Review 3.  A Narrative Review of Where We Are With Point-of-Care Sexually Transmitted Infection Testing in the United States.

Authors:  Charlotte A Gaydos; Yukari C Manabe; Johan H Melendez
Journal:  Sex Transm Dis       Date:  2021-08-01       Impact factor: 2.830

Review 4.  A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men.

Authors:  Barbara Van Der Pol; Charlotte A Gaydos
Journal:  Expert Rev Mol Diagn       Date:  2021-07-12       Impact factor: 5.670

5.  Evaluation of the Diagnostic Efficacy of Xpert CT/NG for Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Tian-Ao Xie; Ye-Ling Liu; Rui-Chun Meng; Xiao-Shan Liu; Ke-Ying Fang; Shu-Ting Deng; Shu-Jin Fan; Chu-Mao Chen; Qin-Rong Lin; Zhi-Jian He; Zhen-Xing Li; Shi Ouyang; Guo-Dong Zhu; Tian-Xing Ji; Yong Xia; Zhi-Yong Pan; Xu-Guang Guo
Journal:  Biomed Res Int       Date:  2020-10-08       Impact factor: 3.411

6.  Clinical Performance of the Xpert® CT/NG Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae: A Multicenter Evaluation in Chinese Urban Hospitals.

Authors:  Yan Han; Mei-Qin Shi; Qing-Ping Jiang; Wen-Jing Le; Xiao-Lin Qin; Han-Zhen Xiong; He-Ping Zheng; Fred C Tenover; Yi-Wei Tang; Yue-Ping Yin
Journal:  Front Cell Infect Microbiol       Date:  2022-01-03       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.